ARTICLE | Company News
Epirus, Ranbaxy launch Remicade biosimilar
December 3, 2014 2:50 AM UTC
Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS) and partner Ranbaxy Laboratories Ltd. (NSE:RANBAXY; BSE:500359) launched Infimab infliximab in India. Infimab is the first biosimilar of Remicade infliximab from Johnson & Johnson (NYSE:JNJ) and Merck & Co. Inc. (NYSE:MRK) approved in India.
India approved Infimab in September. The approval was Epirus' first anywhere (see BioCentury Extra, Sept. 15). ...